巨子生物（02367.HK）今日盘中大涨5.15%，引起市场广泛关注。
该股价上涨主要受到公司2024年度优秀业绩的推动。巨子生物近日发布的2024年年度报告显示，公司财务表现强劲，业务发展迅速。2024年，公司实现收入55.4亿元，同比增长57%；净利润达20.6亿元，同比增长42%，净利率维持在37.2%的高水平。
值得注意的是，巨子生物旗下两大核心品牌表现出色。可复美品牌收入达45.4亿元，同比增长62.9%；可丽金品牌收入8.4亿元，同比增长36.3%。此外，公司线上直销收入同比增长70%，显示出其全渠道战略的成效。公司还宣布计划派息12.4亿元，包括每股0.602元的末期股息和每股0.592元的特别股息。巨子生物在研发方面也有所突破，2024年研发支出1.1亿元，同比增长42.1%，目前拥有188项在研项目和167项专利。公司表示将继续加大海外市场拓展与技术研发投入，为未来增长奠定基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.